The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.
Smart Immune is a clinical-stage biotechnology company focused on developing the next generation of hematopoietic stem cell-based biotherapies to change prognosis and life quality for patients with devastating diseases. The company first cell therapy program is based on T cell progenitors or ProTcellsTM (CD7+/CD34- ; CD5- cells) curative power to enable a short, polyclonal and safe post transplantation immune recovery. This program be completed by integrative developments from targeted conditioning to gene therapy and genome editing enabling clinicians to access new generation treatments for a wide variety of inherited blood disorders and blood cancers.
SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines through its proprietary biotechnology platform. The company utilizes a unique molecular superglue to bond antigens to viruses and other particles, facilitating the rapid creation of vaccines aimed at a variety of diseases. This advanced technology enables medical institutions and research centers to produce next-generation vaccines that demonstrate improved efficacy and reduced development time, thereby enhancing the overall vaccine development process.
Sapient enables the discovery of circulating biomarkers at unprecedented speed and scale. Their platform combines advanced mass spectrometry technologies, computational learning, and the world’s largest proprietary human chemical database to deliver actionable insights that accelerate drug creation. Their methods reduce the time and complexity of biomarker discovery at any phase, helping sponsors select and optimize the best drug candidates for clinical advancement.
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to address life-threatening infections. The company's lead candidate, AR-301, is a fully human IgG1 mAb currently undergoing Phase III trials for treating lung infections linked to S. aureus alphatoxin. Additionally, Aridis is developing several other mAb candidates, including AR-105, in Phase II trials for P. aeruginosa infections, and AR-101, which targets hospital-acquired pneumonia caused by P. aeruginosa serotype O11. Other projects include AR-401, in preclinical stages for Acinetobacter baumannii infections, and AR-201, a preclinical IgG1 mAb for respiratory syncytial virus. The company also has AR-501, an anti-infective therapy in Phase I/IIa clinical trials aimed at managing chronic lung infections in cystic fibrosis patients, as well as acute pneumonia in hospital-acquired pneumonia and ventilator-associated pneumonia settings. Founded in 2003, Aridis is headquartered in San Jose, California.
Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.
Elarex is a Canadian healthcare technology company commercializing its proprietary PT120 formulation technology which has proven to stabilize biologicals (including live vaccines!) so that they are as effective when stored at 40C as if they had been stored at -80C.
Providence Therapeutics Inc. is a biotechnology company based in Toronto, Canada, founded in 2015. The company specializes in the development and production of messenger ribonucleic acid (mRNA) vaccines formulated in lipid nanoparticles. Its portfolio includes PTX-101, a personalized mRNA cancer vaccine aimed at treating advanced ovarian cancer, and various COVID-19 vaccines, including PTX-COVID19-B and PTX-COVID19-T, which target the coronavirus and elicit immune responses against the virus. Providence Therapeutics is committed to creating safe and effective therapies to address unmet medical needs, particularly in oncology and infectious diseases, thereby enhancing the quality of life for patients.
Schrödinger is a healthcare software company that specializes in computational drug design, serving the biopharmaceutical and biotechnology sectors. Founded in 1990, the company operates through two main segments: Software and Drug Discovery. Its software solutions facilitate drug discovery processes for pharmaceutical and industrial clients, as well as academic and governmental research institutions. In addition to software sales, Schrödinger engages in drug discovery through its own preclinical and clinical programs, often collaborating with other organizations. The company is committed to advancing its computational platform by investing in scientific research and talent, and it has established partnerships and collaborations across more than 70 countries. With a workforce of over 400 employees, Schrödinger continues to influence the life sciences and materials science industries through innovative approaches to drug discovery.
Operator of a biopharmaceutical company intended to develop vaccines against infectious diseases. The company offers an end-to-end outsourcing opportunity that includes QC assays, batch records, a full set of documentation and in-person training that helps in contract manufacturing and development services and also provides a fully equipped quality control lab for identity, potency, purity and stability testing, enabling clients to overcome health inequalities and empower people to live healthy lives.
Reithera Srl is a company devoted to develop and produce biopharmaceutical products based on gene delivery technologies for advanced therapies, in order to prevent and treat several serious or life-threatening diseases.
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing proprietary therapeutics for chronic diseases through its innovative ProNeura long-term drug delivery platform. The company's key product, Probuphine, is the first slow-release implant formulation of buprenorphine, designed to provide stable medication levels for up to six months, thereby enhancing patient compliance in the treatment of opioid dependence. Titan also develops ProNeura-Ropinirole, an implant for delivering ropinirole to treat Parkinson's disease, and a similar implant for managing hypothyroidism. The ProNeura technology holds promise for addressing various chronic conditions by ensuring consistent drug delivery, which can improve patient outcomes. In December 2012, Titan entered a licensing agreement granting Braeburn Pharmaceuticals exclusive commercialization rights to Probuphine in the U.S. and Canada, receiving significant financial incentives tied to regulatory approvals and sales milestones. Additionally, Titan receives royalties from the sales of Fanapt, an atypical antipsychotic, further supporting its development efforts.
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.
Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
Developer of a pioneering extended durability mRNA (messenger ribonucleic acid) therapeutics, designed to transform ribonucleic acid drug development into a programmable processor. The company's innovative pipeline is dedicated to tackling unmet medical needs in the realms of metabolic, endocrinologic, and infectious diseases by the utilization of proprietary high-throughput AI (Artificial intelligence)-enabled screening platforms, strategically employed to enhance the stability and facilitate its targeted and selective delivery, enabling scientists to have fully-programmable ribonucleic acid molecules with superior durability and specificity.
CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.
Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.
Sapient enables the discovery of circulating biomarkers at unprecedented speed and scale. Their platform combines advanced mass spectrometry technologies, computational learning, and the world’s largest proprietary human chemical database to deliver actionable insights that accelerate drug creation. Their methods reduce the time and complexity of biomarker discovery at any phase, helping sponsors select and optimize the best drug candidates for clinical advancement.
Dynavax Technologies Corporation is a biopharmaceutical company headquartered in Emeryville, California, specializing in the discovery and development of novel vaccines and treatments for infectious diseases. The company markets HEPLISAV-B, an adjuvanted vaccine for the prevention of hepatitis B infection in adults. Dynavax utilizes its unique Toll-like Receptor Immune Modulation Platform to stimulate the body's immune responses, which is integral to its product development. In addition to its commercial offerings, Dynavax has an active immuno-oncology portfolio, featuring candidates such as SD-101 and DV281. The company is engaged in various research collaborations aimed at developing COVID-19 vaccines, partnering with organizations like Clover Biopharmaceuticals, the University of Queensland, and CEPI. These partnerships reflect Dynavax's commitment to addressing urgent health challenges through innovative vaccine solutions. Founded in 1996, Dynavax has evolved from its original name, Double Helix Corporation, to focus on enhancing immune responses for better disease prevention and treatment.
E25Bio specializes in the development of rapid diagnostic tests for epidemic fever viruses. It is dedicated to preventing severe downstream health outcomes with the use of mobile, fast, real-time reporting to create unprecedented large datasets to guide informed and timely responses for the control of disease spread.
The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.
Vaxxas Pty. Ltd. is an Australian company that specializes in the development and commercialization of innovative vaccine delivery technologies. Established in 2011 and headquartered in Sydney, with an additional office in Cambridge, Massachusetts, Vaxxas focuses on a needle-free delivery system known as the Nanopatch. This system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin, allowing for direct deposition of vaccines among a high concentration of immune cells. By targeting these immunological cells, Vaxxas aims to enhance the activation of the immune system and improve vaccine efficacy, thereby transforming the global landscape of vaccine administration.
Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and preventing diseases associated with human papillomavirus (HPV), cancer, and various infectious diseases. The company's proprietary SynCon immunotherapy design enhances the immune response against cancerous cells and provides broad protection against multiple pathogens. Inovio is actively conducting clinical studies for its DNA medicines, particularly for HPV-related precancers and cancers, as well as other diseases such as glioblastoma, prostate cancer, HIV, and COVID-19. Its lead candidate, VGX-3100, is in Phase 3 trials for treating precancerous cervical dysplasia linked to high-risk HPV types. The company has established partnerships with various organizations, including major pharmaceutical companies and research institutions, to advance its research and development efforts. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals is recognized for its innovative approach to immunotherapy and gene therapy.
Immunocore Limited is a biotechnology company specializing in the discovery and development of innovative T cell receptor-based therapeutics aimed at treating cancer, viral diseases, and autoimmune disorders. Founded in 1999 and headquartered in Abingdon, United Kingdom, with an additional office in Conshohocken, the company has developed a proprietary technology platform that enables the engineering of T cell receptors (TCRs) linked to antibody fragments. This expertise has led to the advancement of IMCgp100, a bi-specific immunotherapeutic currently undergoing clinical trials for metastatic melanoma. Immunocore's focus on addressing diseases with significant unmet medical needs underscores its commitment to advancing novel treatment options.
Immunocore Limited is a biotechnology company specializing in the discovery and development of innovative T cell receptor-based therapeutics aimed at treating cancer, viral diseases, and autoimmune disorders. Founded in 1999 and headquartered in Abingdon, United Kingdom, with an additional office in Conshohocken, the company has developed a proprietary technology platform that enables the engineering of T cell receptors (TCRs) linked to antibody fragments. This expertise has led to the advancement of IMCgp100, a bi-specific immunotherapeutic currently undergoing clinical trials for metastatic melanoma. Immunocore's focus on addressing diseases with significant unmet medical needs underscores its commitment to advancing novel treatment options.
Biological Dynamics Inc. is an early-stage company based in San Diego, California, that focuses on developing a proprietary technology platform utilizing AC Electrokinetic technology for the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This innovative platform allows for the rapid extraction of large molecular weight particles that would not naturally settle. The company offers a range of diagnostic solutions, including the TR(ACE) Assay for monitoring treatment response and tumor burden across various cancers, as well as liquid biopsy testing for personalized medicine applications. Additionally, Biological Dynamics provides clinical laboratory services that encompass molecular and next-generation sequencing. Their technology supports various medical needs, including autoimmune disorders, transplant rejection, infectious diseases, and brain injuries, while also aiding in drug development for conditions like Alzheimer's disease. Founded in 2008, Biological Dynamics aims to enhance disease detection and intervention, ultimately improving patient outcomes and reducing healthcare costs.
Almac Group is a prominent contract development and manufacturing organization based in Craigavon, United Kingdom, specializing in a comprehensive array of services for the pharmaceutical and biotech sectors. With over 40 years of organic growth, the company employs more than 4,500 skilled professionals and operates facilities in the UK, Ireland, the United States, and Asia. Almac Group's offerings encompass research and development, biomarker discovery and development, active pharmaceutical ingredient (API) manufacture, formulation development, clinical trial supply, and companion diagnostic development. The group also includes Almac Diagnostics, which focuses on biomarker discovery and validation, providing services such as bioinformatics solutions and genomic analyses. Additionally, Almac Discovery is dedicated to oncology, concentrating on innovative cancer treatment approaches during the discovery and preclinical stages. Through continuous investment in state-of-the-art technology and services, Almac Group supports clients throughout the entire biopharmaceutical product lifecycle, from preclinical development to commercialization.
Landcent accelerates the fight against global infectious diseases, by developing & delivering affordable, sustainable solutions, that are safe to use at scale.
MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.
RJH Biosciences focus on development of transfection reagents and delivery agents for nucleic acids. The company distributes its products via its website and undertakes projects on new medical treatments.
Enesi Pharma is an innovative pharmaceutical company developing novel products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare. The company’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organizations.
Credence MedSystems, Inc. is a drug delivery and specialty pharmaceutical company based in Menlo Park, California, focused on enhancing the safety of injectable medications for patients and caregivers. The company develops innovative products, including the Companion Staked Needle Syringe, Companion Luer Syringe, and the Epiphany Safety Syringe system, which features a vacuum-triggered, auto-retractable mechanism for safer use. Credence MedSystems aims to simplify the commercialization process for pharmaceutical partners by integrating advanced safety features into existing drug delivery systems without necessitating significant changes to their manufacturing processes. This approach, termed "Innovation Without Change," allows for a more efficient path to market while ensuring that the delivery systems meet high standards of safety and efficacy. The company, formerly known as SafeShot Technologies, Inc., was established in 2011 and has formed a strategic collaboration with SCHOTT AG to further enhance its product offerings.
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.
It was founded in 2010 and is headquartered in Cambridge, Massachusetts.
BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has pioneered innovative therapies through advanced computational discovery and drug development platforms. BioNTech's oncology pipeline includes various neoantigen-targeted therapies, such as NEO-PV-01 for advanced non-small cell lung cancer and multiple FixVac product candidates for different cancers, including melanoma, prostate cancer, and HPV-positive head and neck cancers. The company also explores mRNA vaccine candidates for infectious diseases and maintains collaborations with prominent pharmaceutical firms. BioNTech Cell & Gene Therapies GmbH, a subsidiary, specializes in developing T cell immunotherapies for cancer treatment.
Lyndra Therapeutics, Inc. specializes in the development of ultra-long-acting oral medications that provide sustained drug release over extended periods, ranging from a week to a month. By focusing on orally administered dosage forms that temporarily reside in the stomach, the company aims to transform the way medicines are taken, reducing the need for daily pills. Its portfolio includes therapies targeting a variety of health conditions, such as Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is committed to enhancing medication adherence and improving health outcomes while also aiming to lower healthcare costs through innovative delivery methods.
A biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. It antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines and a variety of other product candidates for emerging viruses.
Biological Dynamics Inc. is an early-stage company based in San Diego, California, that focuses on developing a proprietary technology platform utilizing AC Electrokinetic technology for the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This innovative platform allows for the rapid extraction of large molecular weight particles that would not naturally settle. The company offers a range of diagnostic solutions, including the TR(ACE) Assay for monitoring treatment response and tumor burden across various cancers, as well as liquid biopsy testing for personalized medicine applications. Additionally, Biological Dynamics provides clinical laboratory services that encompass molecular and next-generation sequencing. Their technology supports various medical needs, including autoimmune disorders, transplant rejection, infectious diseases, and brain injuries, while also aiding in drug development for conditions like Alzheimer's disease. Founded in 2008, Biological Dynamics aims to enhance disease detection and intervention, ultimately improving patient outcomes and reducing healthcare costs.
Medsaf is a pharmaceutical supply chain company based in Lagos, Nigeria, founded in 2014. It specializes in the delivery of medications, including antacids, antiviral drugs, antineoplastics, and various supplements, to hospitals, pharmacies, clinics, NGOs, and government entities. Medsaf aims to enhance the availability, affordability, and quality of medications in emerging markets through its end-to-end procurement platform. The company utilizes technology to automate and finance medication procurement, integrating logistics, quality control, and financing services. With a focus on data analytics and blockchain, Medsaf provides stakeholders with essential information regarding the movement of medications, ensuring a more efficient supply chain. The company also offers its products online, expanding access to vital healthcare resources.
Provider of courier services intended to provide medication delivery throughout South Africa. The company's services offer accessible alternatives to the health products distribution and supply chain, deliver life-saving prescription medication and more, providing patients with collection and delivery of chronic medication from public health facilities to their homes.
AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.
Schrödinger is a healthcare software company that specializes in computational drug design, serving the biopharmaceutical and biotechnology sectors. Founded in 1990, the company operates through two main segments: Software and Drug Discovery. Its software solutions facilitate drug discovery processes for pharmaceutical and industrial clients, as well as academic and governmental research institutions. In addition to software sales, Schrödinger engages in drug discovery through its own preclinical and clinical programs, often collaborating with other organizations. The company is committed to advancing its computational platform by investing in scientific research and talent, and it has established partnerships and collaborations across more than 70 countries. With a workforce of over 400 employees, Schrödinger continues to influence the life sciences and materials science industries through innovative approaches to drug discovery.
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.
It was founded in 2010 and is headquartered in Cambridge, Massachusetts.
DelSiTech, Ltd. is a drug delivery and development company based in Turku, Finland, founded in 2001. The company specializes in biodegradable silica-based technology for the controlled release of small molecule drugs, biopharmaceuticals, and viral vectors. DelSiTech focuses on parenteral and local administration, offering products such as long-term drug delivery implants and injectable formulations. Their innovative approach utilizes a silica matrix to embed active ingredients, enabling the development of various dosage forms, including injectable depot, implants, and eye drops. DelSiTech aims to provide solutions for drug-related challenges, supporting clients in developing controlled release supergeneric products.
Lyell Immunopharma is focused on advancing the science of T-cell differentiation, functionality, and specificity so that they can develop curative treatments for human diseases. Lyell Immunopharma is headquartered in South San Francisco, California.
Evolve Biosystems, Inc. is a biotechnology company based in Davis, California, that focuses on developing probiotic-based biotherapeutics aimed at establishing, restoring, and maintaining a healthy human microbiome. The company specializes in addressing gut dysbiosis across all stages of life, with particular emphasis on supporting the microbiome of newborn infants. Evolve Biosystems offers both consumer-directed home use products and hospital-based solutions for neonatal intensive care units. With a discovery platform that also addresses microbiome issues in production animals, the company aims to meet various unmet clinical needs. Founded in 2011, Evolve Biosystems is committed to advancing microbiome health through innovative probiotic solutions.
Recursion Pharmaceuticals is a clinical-stage biotechnology company based in Salt Lake City, Utah, founded in 2013. The company utilizes artificial intelligence, automation, and experimental biology to streamline drug discovery and develop treatments for various diseases modeled at the cellular level. Its innovative platform includes multiple software solutions such as ReChem for chemical compound design, ReScreen for managing complex experiments, and RePredict, which employs machine learning to analyze drug compound relationships. Initially focused on drug repurposing for rare diseases, Recursion has expanded its research to address a wider range of conditions, including aging, inflammation, infectious diseases, and immunology. By leveraging advanced technology and high-throughput automated screening, Recursion Pharmaceuticals aims to create a comprehensive understanding of human cellular biology, significantly enhancing the efficiency and effectiveness of discovering new treatments.
Scripps Research is a leading not-for-profit organization dedicated to advancing biomedical research and education to enhance human health. Established in 1924, it originated from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps. The institute is recognized globally for its significant contributions to health science, including the development of treatments for cancer, rheumatoid arthritis, and hemophilia. With approximately 3,000 employees across its campuses in La Jolla, California, and Jupiter, Florida, Scripps Research is home to renowned scientists, including three Nobel laureates, who are engaged in groundbreaking discoveries. Additionally, its graduate program in biology and chemistry is consistently ranked among the top ten in the United States, reflecting the institute's commitment to education and innovation in the biomedical sciences.
Novartis is a Switzerland-based multinational healthcare company that focuses on developing innovative pharmaceuticals and healthcare solutions to meet the evolving needs of patients globally. Their product portfolio includes treatments in key therapeutic areas such as oncology, rare diseases, neuroscience, immunology, respiratory conditions, and cardio-metabolic diseases. The company is also a leader in animal health, creating medicines for pets, farm animals, and farmed fish to enhance their health and welfare. With a commitment to scientific research, Novartis employs a substantial workforce of scientists and engineers dedicated to advancing drug discovery through advanced technologies and high-throughput screening. They aim to address unmet medical needs, demonstrated by their extensive pipeline of new molecular entities targeting various diseases. Novartis operates globally, with the United States being a significant market, and emphasizes responsible practices within its business strategy to improve overall public health.
Immunethep, SA is a biotechnology company based in Cantanhede, Portugal, focused on developing therapies for immune system-related pathologies. A spin-off from the University of Porto, Immunethep utilizes proprietary technology to address unmet medical needs in the field of infectious diseases. The company has identified a novel mechanism employed by various pathogenic bacteria that suppresses the host immune response. By targeting this mechanism, Immunethep is working on developing broad coverage anti-bacterial immunotherapies. One of the key projects includes the creation of neonatal vaccines designed to protect newborns from bacterial infections that can lead to severe health complications, such as sepsis. This innovative approach aims to enhance immunity in neonates and prevent multi-bacterial infections, contributing to advancements in healthcare.
Ventria Bioscience, Inc. is a biotechnology company based in Fort Collins, Colorado, specializing in the development, manufacturing, and marketing of health and nutrition products. Founded in 1993, the company focuses on human nutrition and therapeutics, offering a range of products that includes lactoferrin and lysozyme glycoproteins, which are utilized for gastrointestinal health and the dietary management of acute diarrhea, as well as for treating topical infections and fungal conditions. Ventria also provides OptiVERO, a specialized cell culture media for vaccine manufacturing, and operates a BioShare program that grants researchers access to recombinant proteins and peptides for various research applications. The company leverages its patented ExpressTec technology, which enhances recombinant protein yield through a plant-based manufacturing process, enabling the development of new biotherapeutics, vaccines, and other biomanufacturing reagents.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Immunocore Limited is a biotechnology company specializing in the discovery and development of innovative T cell receptor-based therapeutics aimed at treating cancer, viral diseases, and autoimmune disorders. Founded in 1999 and headquartered in Abingdon, United Kingdom, with an additional office in Conshohocken, the company has developed a proprietary technology platform that enables the engineering of T cell receptors (TCRs) linked to antibody fragments. This expertise has led to the advancement of IMCgp100, a bi-specific immunotherapeutic currently undergoing clinical trials for metastatic melanoma. Immunocore's focus on addressing diseases with significant unmet medical needs underscores its commitment to advancing novel treatment options.
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. It specializes in developing and commercializing silk biomaterial technologies aimed at improving vaccine delivery and storage. The company has created the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapies, and the MATRIX formulation and drying platform, which enhances the stability of vaccines, therapeutics, and diagnostic products. By utilizing a silk-derived protein, Vaxess enables vaccines to be stored and transported without refrigeration, thereby reducing distribution costs and increasing access to essential healthcare products globally.
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.
Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.
Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.
Mologic Ltd. is a diagnostic product developer based in Thurleigh, United Kingdom, founded in 2003. The company specializes in creating innovative solutions for the research market, focusing on areas such as clinical research, diagnostic development, and microbial physiology. Mologic offers a range of products, including lateral flow kits for human Alpha-1 antitrypsin, desmosine ELISA kits for urine assays, and the fMLP assay kit for measuring fMLP in human urine. In addition to its product lineup, Mologic provides services such as assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies targeting challenging biological entities. The company was established by Paul and Mark Davis, driven by a mission to enhance healthcare and education, thereby improving patient care and quality of life.
Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.
Atomo Diagnostics is an Australian company that specializes in the research, design, development, and manufacturing of medical devices for blood-based rapid testing, applicable for both professional use and self-testing. Founded in 2010 and headquartered in Leichhardt, Australia, the company provides the AtomoRapid RDT platform, which supports various blood-based lateral flow test assays. These devices are utilized in screening for chronic conditions and detecting infectious diseases, including HIV. Atomo Diagnostics focuses on enhancing usability, safety, and accuracy in rapid diagnostic testing by integrating all test components into a streamlined solution, thereby reducing user error rates. The company operates internationally, with a presence in Europe, Asia, Africa, and Central and South America, and is led by a team experienced in commercializing innovative healthcare products. Its commitment to improving user experience distinguishes Atomo Diagnostics in the point-of-care testing market.
Batavia Biosciences is a biotechnology company that specializes in accelerating the development of biopharmaceutical products, including viral and bacterial vaccines, recombinant proteins, antibodies, and gene therapy products. The company offers a comprehensive range of services that encompass candidate selection, production of research materials, and both upstream and downstream process development. Additionally, Batavia Biosciences provides assay development, product characterization, and clinical manufacturing. By leveraging unique technologies such as STEP® protein expression technology and SCOUT® high throughput process technology, the company aims to enhance the efficiency and cost-effectiveness of the early stages of product development. This focus allows Batavia Biosciences to help clients complete their preclinical phases more quickly while improving the likelihood of success in transitioning to clinical trials.
Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.
Hangzhou Just Biotherapeutics, Ltd., also known as Just China, is a biotechnology company founded in 2016 and located in Hangzhou, China. The company specializes in developing antibody and recombinant protein biotherapeutics, focusing on accelerating the development of biomedicines while significantly reducing manufacturing costs. It excels in molecular design, process design, drug product design, and the design of manufacturing facilities. Initially a subsidiary of Just Biotherapeutics, Inc., it became a subsidiary of MabSpace Biosciences Co., Ltd. in January 2019.
Takeda Pharmaceutical Company Limited, founded in 1781 and based in Tokyo, Japan, is a leading research-based pharmaceutical firm. It operates primarily in the pharmaceutical sector, focusing on five core therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively contribute to over 80% of its revenue. The company markets a range of original products, including treatments for cancer, ulcers, hypertension, and diabetes. Takeda's venture capital arm, Takeda Ventures, Inc., specializes in direct and fund of fund investments, primarily targeting therapeutic innovations in cardiometabolic disorders, central nervous system diseases, chronic inflammatory conditions, and oncology. The firm invests globally, with a preference for the United States, Canada, and Europe, aiming to support early-stage companies and foster collaborations that leverage Takeda's extensive research and development capabilities. With a diversified revenue stream—50% from the US, 20% from Japan, and 20% from Europe and Canada—Takeda continues its transformation into an agile global leader in pharmaceuticals.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.
Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources to address significant health challenges, particularly resistant infectious diseases and cancers. Founded to advance the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo utilizes a genome-based, culture-independent platform to discover and characterize small molecules from microbial sources found in soil. By leveraging advancements in DNA sequencing and bioinformatics, the company aims to unlock the therapeutic potential of previously undiscovered molecules encoded in microbial DNA, with a focus on treating conditions that have high unmet medical needs. Lodo Therapeutics, supported by Accelerator Corporation, is headquartered in New York City, where its laboratory and offices are located within the Alexandria Center for Life Science.
Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumors. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, which demonstrates a unique mechanism of action and targets derived from antibodies identified through Atreca's innovative discovery platform. ATRC-101 has shown in vitro reactivity with a significant majority of cancer samples, including those from ovarian, non-small cell lung, colorectal, and breast cancer patients. Additionally, the company has established a strategic research collaboration with Merck Sharp & Dohme Corp. to identify antigenic targets of select antibodies with potential applications in oncology. Founded in 2010, Atreca aims to advance its therapies to improve treatment options for cancer patients.
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.
Ceres Nanosciences, Inc. is a privately held life sciences company based in Manassas, Virginia, specializing in the research, development, and commercialization of sample preparation products and diagnostic tests. Utilizing its proprietary Nanotrap technology, Ceres captures, enriches, and preserves biomarkers, facilitating the early detection of various diseases, including cancer, cardiac conditions, and infectious diseases. The company's offerings include a toolset designed for the enrichment of low abundance biomarkers found in complex biofluids such as serum, plasma, urine, and saliva. Among its products is the Nanotrap Lyme Antigen Test, which directly measures Lyme antigens in urine using a Western Blot format. Ceres is funded through federal agency grants and industry collaborations, and it aims to enhance patient outcomes while reducing healthcare costs through innovative diagnostic solutions.
Schrödinger is a healthcare software company that specializes in computational drug design, serving the biopharmaceutical and biotechnology sectors. Founded in 1990, the company operates through two main segments: Software and Drug Discovery. Its software solutions facilitate drug discovery processes for pharmaceutical and industrial clients, as well as academic and governmental research institutions. In addition to software sales, Schrödinger engages in drug discovery through its own preclinical and clinical programs, often collaborating with other organizations. The company is committed to advancing its computational platform by investing in scientific research and talent, and it has established partnerships and collaborations across more than 70 countries. With a workforce of over 400 employees, Schrödinger continues to influence the life sciences and materials science industries through innovative approaches to drug discovery.
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.
Hangzhou Just Biotherapeutics, Ltd., also known as Just China, is a biotechnology company founded in 2016 and located in Hangzhou, China. The company specializes in developing antibody and recombinant protein biotherapeutics, focusing on accelerating the development of biomedicines while significantly reducing manufacturing costs. It excels in molecular design, process design, drug product design, and the design of manufacturing facilities. Initially a subsidiary of Just Biotherapeutics, Inc., it became a subsidiary of MabSpace Biosciences Co., Ltd. in January 2019.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.
IDRI is a Seattle-based not-for-profit committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of poverty. By integrating capabilities, we strive to create an efficient pathway to bring scientific innovation from the lab to the people who need it most.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Zyomyx has a unique expertise in and passion for tackling difficult “outside-the-box” problems. Highly user-friendly, instrument-free point-of-care tests need to be designed with an advanced level of cartridge engineering and reagent stability, and aligned with aggressive cost targets. Zyomyx specializes in exactly these demanding product requirements. Our immediate focus is an advanced, but simple to use and inexpensive CD4 T-cell point-of-care test that will be launched globally and configured to especially meet the demanding specifications for use in low and middle income countries.
TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and headquartered in Arlington, Massachusetts, the company utilizes its proprietary TetraExpress system to produce recombinant human ion channel proteins and other complex proteins. TetraGenetics offers products such as IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. The company's platform leverages the protist Tetrahymena thermophila to efficiently generate properly folded, functional transmembrane proteins, which are often difficult to express using traditional methods. This technology supports the development of vaccine antigens, monoclonal antibodies, and therapeutic proteins for both human and animal health. Additionally, TetraGenetics has formed a strategic research and development collaboration with Imbrium Therapeutics L.P. to further enhance its offerings in the field of autoimmune diseases and pain management.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumors. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, which demonstrates a unique mechanism of action and targets derived from antibodies identified through Atreca's innovative discovery platform. ATRC-101 has shown in vitro reactivity with a significant majority of cancer samples, including those from ovarian, non-small cell lung, colorectal, and breast cancer patients. Additionally, the company has established a strategic research collaboration with Merck Sharp & Dohme Corp. to identify antigenic targets of select antibodies with potential applications in oncology. Founded in 2010, Atreca aims to advance its therapies to improve treatment options for cancer patients.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
BlueWillow Biologics is a biopharmaceutical company based in Ann Arbor, Michigan, specializing in the development of intranasal vaccines and anti-infective products utilizing patented nanotechnology. Founded in 1999 as NanoBio Corporation, the company shifted its focus in 2016-2017 to intranasal applications after successful research funded by the Gates Foundation and NIH. Its innovative NanoStat vaccine technology utilizes an oil-in-water nanoemulsion to effectively deliver and enhance multiple types of antigens. BlueWillow's product portfolio includes vaccines targeting respiratory and sexually transmitted diseases such as pertussis, influenza, anthrax, HSV2, chlamydia, and HIV, along with NanoBio Protect, a nasal antiseptic solution. The company has established a licensing agreement with Merck for the use of its nanoemulsion adjuvant in intranasal vaccines for RSV and seasonal influenza, and maintains a strategic alliance with Public Health England.
TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and headquartered in Arlington, Massachusetts, the company utilizes its proprietary TetraExpress system to produce recombinant human ion channel proteins and other complex proteins. TetraGenetics offers products such as IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. The company's platform leverages the protist Tetrahymena thermophila to efficiently generate properly folded, functional transmembrane proteins, which are often difficult to express using traditional methods. This technology supports the development of vaccine antigens, monoclonal antibodies, and therapeutic proteins for both human and animal health. Additionally, TetraGenetics has formed a strategic research and development collaboration with Imbrium Therapeutics L.P. to further enhance its offerings in the field of autoimmune diseases and pain management.